Role of metals in neuronal apoptosis: Challenges associated with neurodegeneration

Current Alzheimer Research

Volumn 3, Issue 4, 2006, Pages 311-326

  Bharathi, ^a   Ravid, R ^b   Jagannathan Rao, K S ^a  

^a CENTRAL FOOD TECHNOLOGICAL RESEARCH INSTITUTE   (India)

^b NETHERLANDS BRAIN BANK   (Netherlands)

Author keywords

Alzheimer's disease; Amyloid ; Apoptosis; Metals; Oxidative stress; Reactive oxygen species

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; METAL; METAL CHELATE; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; APOPTOSIS; CELL DEATH; CELL FATE; LIPID PEROXIDATION; NERVE DEGENERATION; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TOXICITY;

AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; BRAIN; ENVIRONMENTAL EXPOSURE; HUMANS; METALS; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 33748464521     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506778249399     Document Type: Review

References (174)

1. Kerr JF, Wyllie AH and Curie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26: 239-257 (1972).
2. Kerr JF. History of the events leading to the formulation of the apoptosis concept. Toxicology 181-182: 471-474 (2002).
3. Wyllie AH, Kerr JF and Currie AR. Cell death: the significance of apoptosis versus necrosis. Int Rev Cytol 68: 251-306 (1980).
4. Desjardins P and Ledoux S. The role of apoptosis in neurodegenerative diseases. Metab Brain Dis 13(2): 79-96 (1998).
5. Wyllie AH. Apoptosis: an overview. Br Med Bull 53(3): 451-465 (1997).
6. Agid Y, Hirsch E, Anglade P, Michel P, Brugg B and Ruberg M. Aging, disease and death of nerve cells. Acta Neurol Belg 219-23 (1996).
7. Burke RE and Kholodilov NG. Programmed cell death: does it play a role in Parkinson's disease? Ann Neurol S126-33 (1998).
8. Kerr JF. Neglected opportunities in apoptosis research. Trends Cell Biol 5(2): 55-57 (1995a).
9. Kerr JF, Gobe GC, Winterford CM, Harmon BV. Anatomical methods in cell death. Methods Cell Biol 46:1-27 (1995b).
10. Simonian NA and Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 36: 83-106 (1996).
11. Bredesen DE. Apoptosis: overview and signal transduction pathways. J Neurotrauma 801-10 (2000).
12. Behl C, Davis JB, Klier FG and Schubert D Amyloid-β-peptide induces necrosis rather than apoptosis. Brain Res 645: 253-264 (1994).
13. Maher P and Schubert D. Signalling by reactive oxygen species in the nervous system. Cell Mol Life Sci (8-9): 1287-1305 (2000).
14. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ and Cotman CW Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 90: 7951-7955 (1993).
15. Behl C, Davis J, Lesley R and Schubert D. Hydrogen peroxide mediates amyloid-β protein toxicity Cell 77: 817-827 (2000).
16. Smith MA, Catherine AR, Nunomura A, Raina AK and Perry G. Oxidative stress in Alzheimer's disease. Biochemica et Biophysica Acta 1502: 139-144 (2000).
17. Perry G, Raina AK, Nunomura A, Wataya T, Sayre LM and Smith MA. How important is oxidative damage? Lessons from Alzheimer's disease. Free Rad Bio Med 28: 831-834 (2000).
18. Friedlandler MD. Apoptosis and caspases in neurodegenerative diseases. N Eng J Med 14: 1365-1375 (2003)
19. Schulz JB and Nicotera P. Introduction: Targeted modulation of neuronal Apoptosis: A double edged Sword?. Brain Pathol 10: 273-275 (2000).
20. Mattson M. Apoptotic and anti-apoptotic synaptic signalling mechanisms. Brain Pathol 10: 276-282 (2000).
21. Gibson RM. Does apoptosis have a role in neurodegeneration? Bio Med J 322: 1539-1540 (2001).
22. Smale G, Nichols NR, Brady DR, Finch CE and Horton WE Jr. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 133: 225-230 (1995).
23. McLachlan DRC. Aluminium and the risk of Alzheimer's disease. Environmetrics 6: 233-275 (1995).
24. Gupta VB, Anitha S, Hegde ML, Zecca L, Garruto RM, Ravid R et al, Aluminum in Alzheimer's disease: Are we still at a cross road. Cell Mol Life Sci 62: 143-158 (2005).
25. Carrington CD, Sheehan Dm and Bolger PM. Hazard assessment of lead. Food Addit Contamin 10: 325-335 (1993).
26. Perry G, Cash AD, Srinivas R and Smith MA. Metal and oxidative homeostasis in Alzheimer's disease. Drug Devel Res 56: 293-299 (2002).
27. Castellani RJ, Honda K, Zhu X, Cash AD, Nunomura A, Perry G and Smith MA. Contribution of redox-active iron and copper to oxidative damage in Alzheimer's disease. Ageing Res Rev 3: 319-326 (2004).
28. Bush AI. Copper, Zinc and the metallobiology of Alzheimer's disease. Alzheimer Dis Assoc Disord 17: 147-150 (2003).
29. Rao KSJ, Shanmugavelu P, Shankar SK, Rukminidevi RP, Rao RV, Pande S, et al. Trace elements in the cerebrospinal fluid in Alzheimer's disease. Alz Rep 6: 4-9 (1999).
30. Rajan MT, Rao KSJ, Mamatha BM, Rao RV, Shanmugavelu P, Menon R and Pavithrin S. Quantification of trace elements in Normal human brain by ICPAES. J Neurol Sci 146: 153-166 (1997).
31. Rao KSJ, Rao RV, Shanmugavelu P and Menon RB. Trace elements in Alzheimer's disease brain. A new hypothesis. Alz Rep 2: 241-246 (1999).
32. Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PLR, Siedlak SL, et al, Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer's disease. Biometals 16: 77-81 (2003).
33. Benzi G and Moretti A. Are reactive oxygen species involved in Alzheimer's disease?. Neurobiol Aging 16 : 661-674 (1995).
34. Bush AI, Pettingell WH, Multhaup G, deParadis M, Vonsattel JP, Gusella JF, et al. Rapid induction of Alzheimer Abeta amyloid formation by zinc. Science 265(5177): 1464-1467 (1994).
35. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE and Bush AI. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem 273: 12817-12826 (1998).
36. Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, et al. A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. J Biol Chem 268 (22):16109-161112 (1993).
37. Stadtman ER. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med 9: 315-325 (1990).
38. Smith MA, Perry G and Richey PL. Oxidative damage in Alzheimer's. Nature 382: 120-121 (1996).
39. Smith MA, Hirai K, Hsiao K, Papolla MA, Harris PL, Siedlak SL et al. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17: 2653-2657 (1997).
40. Langley B and Ratan RV. Oxidative Stress-Induced Death in the Nervous System: Cell Cycle Dependent or Independent? J Neurosci Res 77: 621-629 (2004).
41. Varadarajan S, Kanski J, Aksenova M, Lauderback C and Butterfield DA. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ(1-42) and Aβ(25-35). J Am Chem Soc 123 5625-5631 (2001).
42. Pogocki D and Schfneich CH. Redox properties of Met35 in neurotoxic β-amyloid peptide. a molecular modeling study. Chem Res Toxicol 15: 408- 418 (2002).
43. Kanski J, Aksenova M, Schfneich CH and Butterfield DA. Substitution of isoleucine-31 by helix-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid β-peptide (1-42). Free Radic Biol Med 32: 1205- 1211 (2002).
44. Schoneich C. Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer's disease. Biochimica Biophysica Acta 1703: 111-119 (2005).
45. Anitha S, Stein R, Rao KSJ, Latha KS and Viswamitra MA. A link between apoptotic DNA damage and DNA topology in Alzheimer's disease brain: A hypothesis. Alz Rep 4(3): 121-131 (2001).
46. Nunomura A, Perry G and Aliev G. Oxidative damage is the earliest event in Alzheimer's disease. J Neuropathol Exp Neurol 60: 759-767 (2001).
47. Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71: 2034-2040 (1998).
48. Tan Z, Sun N and Schreiber SS. Inmunohistochemical localization of redox factor-1 (Ref-1) in Alzheimer's hippocampus. Neureport 9: 2749-2752 (1998).
49. Hermon M, Cairns N, Egly JM, Fery A, Labudova O and Lubec G. Expression of DNA excision-repair-cross-complementing proteins p80 and p89 in brain of patients with Down's syndrome and Alzheimer's disease. Neurosci Lett 251: 45-48 (1998).
50. Lovell MA, Gabbita SP and Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 72: 771-776 (1999).
51. Honda K, Smith MA, Zhu X, Baus D, Merrick WC, Tartakoff AM, et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 280 (22): 20978-20986 (2005).
52. Honda K, Casadesus G, Petersen RB, Perry G and Smith MA. Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci 1012: 179-182 (2004).
53. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19(6):1959-64 (1999).
54. Lovell MA, Ehmann WD, Butler SM and Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45: 1594-1601 (1995).
55. Koppal T, Subramaniam R, Drake J, Prasad MR, Dhillon H and Butterfield DA. Vitamin E protects against Alzheimer's amyloid peptide-(25±35) induced changes in neocortical synaptosomal membrane lipid structure and composition. Brain Res. 786: 270-273 (1998).
56. Mark RJ, Fuson KS and May PC. Characterization of 8-epiprostaglandin F2a as a marker of amyloid β-peptide-induced oxidative damage. J Neurochem 72: 1146-1153 (1999).
57. Esterbauer H, Schaur RJ and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-129 (1991).
58. Mark RJ, Lovell MA, Markesbery WR, Uchida K and Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J Neurochem 68: 255- 264 (1997).
59. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, et al. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid β-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 69: 273-284 (1997a).
60. Mattson MP, Goodman Y, Luo H, Fu W and Furukawa K. Activation of NF-κb protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res 49: 681-697 (1997).
61. Davis DR, Anderton BH, Brion JP, Reynolds CH and Hanger DP. Oxidative stress induces dephosphorylation of tau in rat brain primary neuronal cultures. J Neurochem 68: 1590-1597 (1997).
62. Montine TJ, Amarnath V, Martin ME, Strittmatter WJ and Graham DG. E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Am J Pathol 148: 89-93 (1996).
63. Lovell MA, Ehmann WD, Mattson MP and Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18: 457-461 (1997).
64. Scandalios JG. Oxidative stress responses - what have genome-scale studies taught us? Genome Biol 3(7) (2002).
65. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 7: 298-304 (2000).
66. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol (2): 119-130 (1992).
67. Kokoszka JE, Coskun P, Esposito LA and Wallace DC. Increased mitochondrial oxidative stress in the Sod2 (+/-) mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. Proc Natl Acad Sci USA 5: 2278-2283 (2001).
68. Kruman II, Nath A and Mattson MP. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol 154(2): 276-88 (1998).
69. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Beher D, Masters CL, et al. Reactive oxygen species and Alzheimer's disease. Biochem Pharmacol 54: 533-539 (1997).
70. Halliwell B and Gutteridge JM. Lipid peroxidation, oxygen radicals, cell damage, and antioxidant therapy. Lancet 1: 1396-1397 (1984).
71. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, et al. Aluminum, iron and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J Neurochem 61: 1171-1174 (1993).
72. Good PF, Perl DP, Bierer LM and Schmeidler J. Selective accumulation of aluminium and iron in the neurofibrilary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol 31: 286-292 (1992).
73. Richardson JS. Free radicals in the genesis of Alzheimer's disease. Ann NY Acad Sci 695: 73-76 (1993).
74. Connor JR, Snyder BS, Beard JL, Fine RE and Mufson EJ. Regional distribution of iron and iron regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 31: 327-335 (1992).
75. Kala SV, Hasino, BB and Richardson JS. Brain samples from Alzheimer's patients have elevated levels of loosely bound iron. Int J Neurosci 86: 263-269 (1996).
76. Bondy SC, Guo-Ross SX and Truong AT. Promotion of transition metal-induced reactive oxygen species formation by β-amyloid. Brain Res 799: 91-96 (1998).
77. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, et al. The amyloid-β-peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616 (1999a).
78. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, et al. Cu(II) potentiation of Alzheimer Aβ neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 74: 37111-37116 (1999b).
79. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL and Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52 (1998).
80. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 18: 172-176 (1995).
81. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, et al. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70: 2212-2215 (1998).
82. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, et al. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 43(2):560-8 (2004).
83. Dyrks T, Dyrks E, Hartmann T, Masters C and Beyreuter K. Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem 267: 18210-18217 (1992).
84. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, et al. Aluminum, iron and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J Neurochem 61: 1171-1174 (1993).
85. Gerlach M, Ben-Shachar D, Riederer P and Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative disease? J Neurochem 63: 793-807 (1994).
86. Sayre LM, Perry G and Smith MA. Redox metals and neurodegenerative disease. Curr Opin Chem Biol 3: 220-225 (1999).
87. Mielke K and Herdegen T. JNK and p38 stresskinases-degenerative effectors of signal transduction-cascades in the nervous system, Prog Neurobiol 61: 45-60 (2000).
88. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B and Cowburn RF. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration, J Alzheimer's Dis 3: 41- 48 (2001).
89. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91: 5710- 5714 (1994).
90. Zhu X, Rottkamp CA, Zevez K, Atwood CS, Perry G and Smith MA. Metal-mediated amyloid-beta toxicity acts through the activation of JNK/SAPK pathway in Alzheimer disease. Free Radic Biol Med 31 S65(2001).
91. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS and Perry G. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev 123: 39-46(2001).
92. Connor JR and Menzies SL. Cellular management of iron in the brain. J Neurol Sci 134 Suppl: 33-44 (1995).
93. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H and Smith MA. Activation and redistribution of c-Jun N-terminal kinase/ stress activated protein kinase in degenerating neurons in Alzheimer's disease, J. Neurochem. 76 (2001) 435-441.
94. Zhu X, Lee H-G, Perry G, Raina AK and Smith MA. The MAPK pathways in Alzheimer's Disease. NeuroSignals 11: 270-281 (2002).
95. Shoji M, Iwakami N, Takeuchi S, Waragai M, Suzuki M, Kanazawa I, et al. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res Mol Brain Res (1-2): 221-33 (2000).
96. Ferrer I, Blanco R, Carmona M and Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 108: 1397-415 (2001).
97. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF, et al. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis 3(1): 41-48 (2001).
98. Luth HJ, Holzer M, Gertz HJ and Arendt T. Aberrant expression of nNOS in pyramidal neurons in Alzheimer's disease is highly colocalized with p21ras and p16INK4a. Brain Res 852: 45-55 (2000).
99. Perry G, Nunomura A and Smith MA. A suicide note from Alzheimer's disease neurons? Nat Med 4: 897-898 (1998).
100. Perry G, Zhu X and Smith MA. Do neurons have a choice in death? Am J Pathol 158: 1-2 (2001).
101. Wiese AG, Pacifici RE, Davies KJ. Transient adaptation of oxidative stress in mammalian cells. Arch Biochem Biophys 318: 231-40 (1995).
102. Davies JM, Lowry CV, Davies KJ. Transient adaptation to oxidative stress in yeast. Arch Biochem Biophys 317: 1-6 (1995).
103. Keyse SM, and Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 86: 99-103 (1989).
104. Rushmore TH, King RG, Paulson KE and Pickett CB. Regulation of glutathione S-transferase Ya subunit gene expression: identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc Natl Acad Sci USA 87: 3826-30 (1990).
105. Chao M, Zhu X, Raina AK. Sources contributing to the initiation and propagation of oxidative stress in Alzheimer's disease. Proc Indian Natl Sci Acad B 69: 251-60 (2003).
106. LeBel CP and Bondy SC. Oxidative damage and cerebral aging. Prog Neurobiol 38: 601-609 (1992).
107. Mattson MP, Chan SL and Duan W. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev 82: 637-672 (2002).
108. Duchen MR. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Aspects Med 25: 365-451 (2004).
109. Ojaimi J and Byrne E. Mitochondrial functional and Alzheimer's disease. Biol Signals Recept 10: 254-262 (2001).
110. Eckert A, Keil U, Merques CA, Bonert A, frey C, Schussel K, et al. Mitochondrial dysfunction, apoptotic cell death and Alzheimer's disease. Biochem Pharmacol 66: 1627-1634 (2003).
111. Smith MA, Hirai K, Nunomura A and Perry G. Mitochondrial abnormalities: a primary basis for oxidative damage in Alzheimer's disease. Drug Dev Res 46: 26-33 (1999).
112. Smith MA, Hirai K, Nunomura A and Perry G. Mitochondrial abnormalities in Alzheimer's disease. Fourth European Meeting on Mitochondrial Pathology p 203.
113. Kroemer G and Reed JC. Mitochondrial control of cell death. Nat Med 6: 513-519 (2000)
114. Takuma K, Yan SS, Stern DM, Yamada K. Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. J Pharmacol Sci (3): 312-6 (2005).
115. Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schussel K and Muller WE. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochemical Pharmacology 66: 1627-1634 (2003).
116. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21: 3017-3023 (2001).
117. Beal MF. Mitochondria, free radicals and neurodegeneration. Curr Opin Neurobiol 6: 661-666 (1996).
118. Zhu X, Smith MA, Perry G and Aliev G. Mitochondrial failures in Alzheimer's disease. Am J Alzheimers Other Demen 19: 345-352 (2004).
119. Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T and Tohyama M. Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat (1-2): 67-78 (2004).
120. Rao RV, Hermel E, Castro-Obregon S, del Rio G, Ellerby LM, et al. Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. J Biol Chem 276 (36): 33869-33874 (2001).
121. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by β-amyloid. Nature 403: 98-103 (2000).
122. Mattson MP, Gary DS, Chan SL and Duan W. Perturbed endoplasmic reticulum function, synaptic apoptosis and the pathogenesis of Alzheimer's disease. Biochem Soc Symp (67): 151-62 (2001).
123. Katayama T, Imaizumi K, Honda A, Yoneda T, Kudo T, et al. Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. J Biol Chem 276(46): 43446-54 (2001).
124. Siman R, Flood DG, Thinakaran G and Neumar RW. Endoplasmic reticulum stress-induced cysteine protease activation in cortical neurons: effect of an Alzheimer's disease-linked presenilin-1 knock-in mutation. J Biol Chem 276(48): 44736-43 (2001).
125. Marques CA, Keil U, Bonert A, Steiner B, Haass C, Muller WE and Eckert A. Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway. J Biol Chem 278 (30): 28294-28302 (2003).
126. Eldadah BA and Faden AI. Caspase pathways, neuronal apoptosis, and CNS injury. J Neurotrauma (10): 811-29 (2000).
127. Soto C. Protein misfolding and disease: Protein refolding and therapy. FEBS Letts 498: 204-207 (2001).
128. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 26: 207-214 (2003).
129. Bush AI. Metals and neuroscience. Curr Opin Chem Biol 4: 184-191 (2000).
130. Wolozin B and Behl C. Mechanism of Neurodegenerative disorders. Part I: Protein aggregates. Arch Neurol 793-796 (2000).
131. Wolozin B and Behl C. Mechanism of Neurodegenerative disorders. Part 2: Control of cell death. Arch Neurol 801-804 (2000).
132. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al. Dramatic aggregation of Alzheimer abeta by Cu (II) is induced by conditions representing physiological acidosis. J Biol Chem 273(21): 12817-12826.(1998).
133. McGeer PL and McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21: 195-218 (1995).
134. Wyss-Coray Tand Mucke L. Inflammation in neurodegenerative disease-a double edged sword. Neuron 35: 419-432 (2002).
135. Itagaki S, McGeer PL, Akiyama H, Zhu S and Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease. J neuroimmunol 24: 173-182. (1989).
136. Yip CM and McLaurin J. Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption. Biophys J 80(3): 1359-71 (2001).
137. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA and Butterfield DA. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc Natl Acad Sci USA 91: 3270-3274 (1994).
138. Sayre LM, Zagorski MG, Surewicz WK, Krafft GA and Perry G. Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal. Chem Res Toxicol 10(5): 518-26 (1997).
139. Huang X, Cuajungco MP, Atwood CS, Haertshorn MA, Tyndall JDA, Hanson GR, et al. Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cellfree hydrogen peroxide production and metal reduction. J Biol Chem 274: 37111- 37116 (1999).
140. Yan S, Chen X and Fu J. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691 (1996).
141. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC and Loike JD. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382(6593): 716-719 (1996).
142. Paresce DM, Ghosh RN and Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 3: 553-565 (1996).
143. Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T, Tohyama M, Ogawa S, Roher A, Stern D. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature. 389(6652):689-695 (1997).
144. Tamagno E, Parola M, Guglielmotto M, Santoro G, Bardini P, Marra L, et al. Multiple signalling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radic Biol Med 35 (1): 45-58 (2003).
145. 2, Caspase-3, NF-κB, p53 and c-Jun. Neurotoxiocology 23: 351-365 (2002).
146. Kerr JFR, Gobe GC, Winterford CM and Harmon BV. Anatomical methods in cell death. In: Schwartz LM, Osborne BA, editors. Methods in cell biology: cell death. New York: Academic Press p. 1-27 (1995).
147. Savory J, Herman MM and Ghribi O. Intracellular mechanisms underlying aluminium-induced apoptosis in rabbit brain. J Inorg Biochem 97: 157-154 (2003).
148. Ghribi O, Herman MM, Dewitt DA, Forbes MS and Savory J. Abeta (1-42) and aluminium induce stress in the endoplasmic reticulum in rabbit hippocampus, involving nuclear translocation of gadd 153 and NF-kappa B. Brain Res Mol Brain Res 96: 30-38 (2001).
149. Adams JM and Cory S. The Bcl-2 protein Family arbiters of cell survival. Science 281: 1322-1326 (1998).
150. 2+ ions. J Cell Biol. 143 (1998) 217-224.
151. Ghribi O, Dewitt DA, Forbes MS, Herman MM and Savory J. Involvement of mitochondria and endoplasmic reticulum in regulation of apoptosis: changes in cytochrome-c, Bcl-2 and Bax in the hippocampus of Aluminium treated rabbits. Brain Res 8: 764-73 (2001).
152. D'mello SR, Anelli R and Calissano P. Induction of apoptosis in immature granule cells but promotes survival of mature neurons. Exp Cell Res 211: 232-238 (1994).
153. Savory J, Rao, KSJ and Huang Y. Age related hippocampal changes in Bcl-2: Bax ratio, oxidative stress, redox-active iron and apoptosis associated with aluminium-induced neurodegeneration: Increased susceptibility with aging. Neurotoxicol 20: 805-815 (1999).
154. Savory J, Ghribi O, Forbes MS and Herman MM. Aluminium and neuronal cell injury: inter-relationships between neurofilamentous arrays and apoptosis. J Inorg Biochem 87: 15-19 (2001).
155. Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, Cotman CW, et al. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol 158: 189-198 (2001).
156. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic Abeta peptide formation. Cell 97: 395-406 (1999).
157. Perry G, Nunomura A, Lucassen P, Lassmann H and Smith MA. Apoptosis and Alzheimer's disease (letter). Science 282: 1268-1269 (1998).
158. Perry G, Nunomura A, Raina AK and Smith MA. Amyloid-β junkies. Lancet 355: 757 (2000).
159. Salehi A, Ravid R, Gonatas NK and Swaab DF. Decreased activity of hippocampal neurons in Alzheimer's disease is not related to the presence of neuro-fibrillary tangles. J Neuropathol Exp Neurol 54: 704-709 (1995).
160. Slater AF, Stefan C, Nobel I, Van-dev Dobbelsteen DJ and Orrenius S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol Lett 82-83: 149-153 (1995).
161. Sperandio S, de Belle I and Bredesen DE. An alternative, non-apoptotic form of programmed cell death. Proc Natl Acad Sci U S A 97(26):14376-81 (2000).
162. Raina AK, Hochman A, Ickes H II, Zhu X, Ogawa O, Cash AD, Shimohama S et al. Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out?. Prog Neuro-Psychopharmacol Biol Psych 27: 251-254 (2003).
163. Raina Ak, Hochamn A, Zhu X, Rottkamp CA, Nunomura A, Siedlak SL, et al. Abortive apoptosis in Alzheimer's disease. Acta Neuropathol (Berl) 4: 305-310 (2001).
164. Ravid R, Van Zwieten EJ and Swaab DF. Brain banking and the human hypothalamus factors to match for, pitfalls and potentials. Prog Brain Res 93: 83-95 (1992).
165. Bonkale WL, Fastborn J, Weighager B, Ravid R, Winblad B, Cowburn RF. Impaired G-protein stimulated adenylyl cyclase activity in Alzheimer's disease brain is not accompanied by reduced cyclic-AMP-dependent protein kinase A activity. Brain Res 737: 155-161.
166. Langley B and Ratan RV. Oxidative Stress-Induced Death in the Nervous System: Cell Cycle Dependent or Independent? J Neurosci Res 77: 621-629 (2004).
167. Catherine AR, Nunomura A, Hirai K, Sayre LM, Perry G and Smith MA. Will antioxidants fulfill their expectations for the treatment of Alzheimer's disease? Mech Aging Dev 116: 169-179 (2000).
168. Behl C and Moosmann B. Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. J Biol Chem 383(3-4): 521-36 (2002).
169. Doraiswamy PM and Finefrock AE Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol 7: 431-434 (2004).
170. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem. 274 (33): 23223-23228 (1999).
171. Danscher G, Jensen KB, Frederickson CJ, Kemp K, Andreasen A, Juhl S, et al. Increased amount of zinc in the hippocampus and amygdale of Alzheimer's diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. Neurosci Methods 76: 53-59 (1997).
172. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (3):665-76 (2001).
173. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75(3): 1219-33 (2000).
174. Richardson DR. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann N Y Acad Sci 1012: 326-341 (2004).